Fractyl Health (NASDAQ:GUTS) Stock Price Target Cut by Morgan Stanley

Posted by Brenda Bartman on Oct 19th, 2026

Fractyl Health (NASDAQ:GUTS – Get Free Report) had its target price reduced by research analysts at Morgan Stanley to $4.00 in a report released on Monday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s price target indicates a potential upside of 189.86% from the company’s previous close.

GUTS has been the subject of several other research reports. Weiss Ratings lowered Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. Wall Street Zen downgraded Fractyl Health from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Craig Hallum set a $5.00 price target on Fractyl Health in a research report on Monday. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $50.25.

Check Out Our Latest Research Report on Fractyl Health

Fractyl Health Stock Down 11.0%

NASDAQ GUTS traded down $0.17 during trading hours on Monday, reaching $1.38. 1,131,434 shares of the company’s stock were exchanged, compared to its average volume of 330,602. The company’s 50-day moving average is $6.89 and its two-hundred day moving average is $8.06. Fractyl Health has a one year low of $1.37 and a one year high of $29.34. The company has a debt-to-equity ratio of 1.41, a quick ratio of 3.15 and a current ratio of 3.15. The company has a market capitalization of $18.30 million, a price-to-earnings ratio of -0.13 and a beta of 2.42.

Fractyl Health (NASDAQ:GUTS – Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($1.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.62) by $0.18. On average, analysts forecast that Fractyl Health will post -6.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

Institutional investors and hedge funds have recently bought and sold shares of the company. Nantahala Capital Management LLC bought a new position in shares of Fractyl Health in the second quarter worth about $8,968,058. General Catalyst Group Management LLC bought a new position in shares of Fractyl Health in the second quarter worth about $3,880,000. Bank of America Corp DE bought a new position in shares of Fractyl Health in the second quarter worth about $4,791,000. Sanctuary Advisors LLC bought a new position in shares of Fractyl Health in the second quarter worth about $26,000. Finally, PEAK6 LLC bought a new position in shares of Fractyl Health in the 2nd quarter valued at $159,000.

About Fractyl Health

(Get Free Report)

Fractyl Health, Inc is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including type 2 diabetes and obesity. The company’s approach is based on targeting the biology of the gastrointestinal system and developing treatments intended to address underlying disease mechanisms rather than relying solely on chronic medication.

Fractyl Health’s lead product candidate is Revita, an investigational, minimally invasive endoscopic procedure designed to resurface the duodenal lining.